Primary Ovarian Insufficiency and Surgical Menopause: Why Care Is Different Before Age 45

Written By Dr. Kristen Wolfe, MD

What Is Primary Ovarian Insufficiency?

Primary ovarian insufficiency (POI) occurs when the ovaries stop functioning normally before age 40.

Women with POI may experience:

  • Irregular or absent menstrual cycles

  • Infertility or difficulty conceiving

  • Hot flashes or night sweats

  • Vaginal dryness

  • Sleep or mood changes

Unlike typical menopause, ovarian function in POI can sometimes be intermittent, meaning hormone levels may fluctuate and occasional ovulation may still occur.

POI can develop for several reasons, including:

  • Genetic conditions

  • Autoimmune disorders

  • Medical treatments such as chemotherapy or radiation

  • Unknown causes (which account for most cases)

What Is Surgical Menopause?

Surgical menopause occurs when both ovaries are removed, typically during procedures such as bilateral oophorectomy or hysterectomy with removal of the ovaries.

Because the ovaries are the body’s primary source of estrogen before menopause, their removal causes a sudden and dramatic drop in hormone levels.

This situation can occur for several reasons, including treatment for gynecologic conditions, but also preventive surgery in women with hereditary cancer risk.

Women with BRCA1, BRCA2, or other hereditary cancer syndromes may choose risk-reducing removal of the ovaries and fallopian tubes (often called risk-reducing salpingo-oophorectomy) to lower the risk of ovarian cancer.

Symptoms often include:

  • Immediate hot flashes and night sweats

  • Sleep disruption

  • Mood changes

  • Vaginal dryness or pain with intercourse

  • Reduced libido

Symptoms may be more abrupt and severe than natural menopause because the hormonal change occurs suddenly rather than gradually.

What About Hysterectomy With Ovaries Retained?

Many women are told that if they have a hysterectomy but keep their ovaries, they will not go through menopause early.

While it is true that removing the uterus alone does not cause immediate menopause, research suggests ovarian function may still decline earlier than expected in many women after hysterectomy.

A large prospective cohort study found that women who underwent hysterectomy with ovarian preservation had nearly twice the risk of ovarian failure compared with women who had not had the surgery.

In that study, about 14.8% of women with hysterectomy experienced ovarian failure within four years, compared with 8% of women with intact uteri.

Other research has similarly found that menopause may occur about 1–2 years earlier on average after hysterectomy, even when both ovaries remain in place.

Researchers believe several factors may contribute:

  • Changes in blood flow to the ovaries after uterine surgery

  • Surgical disruption of ovarian support structures

  • Underlying gynecologic conditions affecting ovarian function

Another important issue is that menopause may be harder to recognize after hysterectomy.

Without menstrual cycles as a signal, hormonal changes may go unnoticed until symptoms become significant.

For this reason, women who undergo hysterectomy in their 30s or 40s—even when the ovaries are preserved—should be aware that menopause may occur earlier than expected, and symptoms such as hot flashes, sleep disruption, mood changes, or vaginal dryness deserve attention.

Why Early Estrogen Loss Matters

Key points to know:

  • Early menopause is not simply an earlier version of natural menopause

  • In most cases, hormone therapy is recommended unless there is a medical contraindication

  • Treatment should usually continue until at least the natural age of menopause (around age 50–51)

  • For women with POI, hormone therapy does not increase breast cancer risk

  • Women who undergo risk-reducing ovary removal (for example due to BRCA mutations) often benefit from hormone therapy as well

  • The goal is true hormone replacement, not just symptom relief

  • Women who undergo hysterectomy but retain their ovaries may also experience earlier menopause, and this can go unrecognized because menstrual cycles are no longer present

Untreated early menopause should be considered a serious medical issue. Prolonged estrogen deficiency in a young woman increases the risk of osteoporosis, cardiovascular disease, dementia, and other long-term health problems.

This is not just about hot flashes.

It is about protecting long-term health.

Estrogen plays important roles throughout the body. It helps regulate:

  • Bone density

  • Cardiovascular health

  • Brain and cognitive function

  • Metabolic processes

  • Genitourinary tissue health

When estrogen levels fall decades earlier than expected, the consequences extend far beyond menopause symptoms.

Research shows untreated early menopause is associated with increased risks of:

  • Osteoporosis and fractures

  • Cardiovascular disease

  • Cognitive decline

  • Mood disorders

  • Genitourinary syndrome of menopause

For this reason, menopause before age 45 represents a major hormonal deficiency state, not simply a symptom issue.

Hormone Therapy Is Usually Recommended

For women with primary ovarian insufficiency or surgical menopause before age 45, major medical societies—including American College of Obstetricians and Gynecologists and The Menopause Society—recommend systemic hormone therapy unless there is a medical contraindication.

ACOG specifically recommends that treatment for women with primary ovarian insufficiency continue until the average age of natural menopause (around age 50–51).

Importantly, in this setting hormone therapy is not just symptom management.

It is true hormone replacement, intended to restore estrogen levels closer to what the body would normally produce before natural menopause.

Stopping hormones earlier may expose women to years of unnecessary estrogen deficiency.

Is Hormone Therapy Safe in Early Menopause?

Many of the safety concerns women have heard about hormone therapy come from studies of older postmenopausal women, often years after menopause, who were more likely to already have conditions such as coronary artery disease, vascular disease, or other cardiometabolic risk factors. That is very different from a healthy woman in her 30s or 40s with primary ovarian insufficiency or surgical menopause, whose body would normally still be producing estrogen. In younger women with early estrogen loss, hormone therapy is generally being used as physiologic replacement, not as late intervention in a potentially already higher-risk population. This distinction matters, especially because risks seen in some studies were influenced by age, time since menopause, route of administration, and baseline health status. 

Many older women benefit from the safety advantages of transdermal estradiol, particularly when clotting or vascular risk is a concern. But for the majority of otherwise healthy younger women with POI or surgical menopause, oral estradiol is also generally a safe and appropriate option. In this setting, the choice between oral and transdermal estradiol is often about individual preference, symptom profile, and personal risk factors. 

What About Testosterone After Surgical Menopause?

When both ovaries are removed, the body loses a major source of testosterone as well as estrogen.

That matters.

Surgical menopause is not just about hot flashes. Some women notice major shifts in:

  • Libido

  • Arousal

  • Sexual response

  • Energy

  • Overall vitality

Estrogen replacement remains the foundational treatment.

But because ovarian removal also reduces androgen production, women who experience persistent sexual symptoms should have a thoughtful discussion about whether testosterone may also be appropriate.

Other Health Considerations

Women experiencing menopause before age 45 may benefit from additional health monitoring and prevention strategies, including:

  • Bone density screening

  • Attention to cardiovascular risk factors

  • Nutrition strategies that support bone health

  • Physical activity including resistance training

  • Evaluation and treatment of sexual health concerns

Early menopause can also have emotional and psychological impacts, particularly when it occurs unexpectedly or affects fertility.

Comprehensive care should address both physical and emotional health.

The Role of Personalized Care

Primary ovarian insufficiency and surgical menopause are not simply earlier versions of natural menopause.

They represent a distinct medical situation that requires thoughtful care and long-term planning.

Women experiencing early menopause should not have to fight to access evidence-based treatment.

At Evermore Women’s Health, we focus on personalized, evidence-based care for women navigating complex hormonal transitions—including early menopause, cancer survivorship, and surgical menopause.


References: 

Dr. Kristen Wolfe, MD

Dr. Kristen Wolfe, MD, is a board-certified OB/GYN and the founder of Evermore Women’s Health, a women-led, patient-centered practice dedicated to helping women navigate midlife with clarity, confidence, and evidence-based care. She specializes in perimenopause, menopause, sexual health, and the hormonal, metabolic, and preventive health needs that arise during this stage of life. She takes a collaborative, personalized approach to care, ensuring that each treatment plan is rooted in her patients’ goals, values, and real-world needs.

Previous

Perimenopause Symptoms: What Decades of Research From the Seattle Midlife Women’s Health Study Reveal
Next

Menopause Supplements: Evidence on Black Cohosh, Soy, Relizen, Amberen & More